Standard BioTools Inc. (LAB) bonds
LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 12/3085% below fair value
$0.71+0.06 (+8.60%)
Close on Nov 13, 2026Market cap $277.71MP/E 3.2Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Standard BioTools reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2023
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in Standard BioTools's 10-Q for the period ended Jun 30, 2026
| Issue | Coupon | Matures | Amount issued |
|---|---|---|---|
| Unsecured Convertible Note Due 2027 Convertible | 8.00% | 2027 | $5.00M |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
See a number that looks wrong?